You are now leaving this web site

This Web site may contain links or references to other Web sites maintained by third parties over whom Teva, Inc. ("Teva") has no control. Links are provided as a convenient resource to our visitors. We carefully choose Web sites which we believe are useful based on our high standards. However, Web sites can change. Teva cannot guarantee the standards of every Web site link or be responsible for the content of non-Teva Web sites. Inclusion of any third-party link does not imply an endorsement or recommendation by Teva.

Similarly, this Web site may be accessed from third-party links over which Teva has no control. Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of any information contained in such Web sites and shall have no liability for any damages or injuries of any kind arising from such content or information.

Adverse reactions reported by ≥2% of patients on AJOVY and greater than placebo¹

	AJOVY 225 mg Monthly (n=290)	AJOVY 675 Mg Quarterly (n=667)	Placebo Monthly (n=668)
Injection-site reactions*	43%	45%	38%

^{*Injection-site reactions include multiple adverse reactions–related terms, such as injection-site pain, induration, and erythema.}

The safety of AJOVY was evaluated in two phase 3 clinical trials¹

Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration¹
AJOVY is fully humanized¹
- Humanization is a process designed to reduce immunogenicity²
- Less than 1% of patients in both phase 3 trials developed antibodies to AJOVY³

≤2% of patients discontinued due to adverse events in both phase 3 trials in the AJOVY and placebo treatment arms³

Most injection-site reactions were rated as mild to moderate in severity³

In both phase 3 treatment arms,³

Less than 1% of patients experienced depression or weight gain vs <1% for placebo
No patients experienced memory loss vs <1% for placebo

Suggestions to explore next

AJOVY helped significantly reduce monthly migraine days vs placebo¹
see the clinical trial data for ajovy

Savings Offer for AJOVY
download savings offer

AJOVY is a monoclonal antibody that selectively targets the CGRP ligand¹
see how ajovy works

Adverse reactions reported by ≥2% of patients on AJOVY and greater than placebo1

The safety of AJOVY was evaluated in two phase 3 clinical trials1

≤2% of patients discontinued due to adverse events in both phase 3 trials in the AJOVY and placebo treatment arms3

Suggestions to explore next

Adverse reactions reported by ≥2% of patients on AJOVY and greater than placebo¹

The safety of AJOVY was evaluated in two phase 3 clinical trials¹

≤2% of patients discontinued due to adverse events in both phase 3 trials in the AJOVY and placebo treatment arms³